Table 1.
Patient information
| Gender | |
| Male | 314 (68.41%) |
| Female | 145 (31.59%) |
| Age at surgery | |
| ≤ 60 | 271 (59.04%) |
| > 60 | 188 (40.96%) |
| Tumor size | |
| < 4.0 | 66 (14.38%) |
| ≥ 4.0 | 393 (85.62%) |
| Tumor location | |
| Upper third | 113 (24.62%) |
| Middle third | 117 (25.49%) |
| Lower third | 201 (43.79%) |
| More than 2/3 stomach | 28 (6.1%) |
| Depth of tumor invasion (T stage) | |
| T1 | 6 (1.31%) |
| T2 | 46 (10.02%) |
| T3 | 284 (61.87%) |
| T4 | 123 (26.80%) |
| Number of metastatic lymph nodes (N stage) | |
| N0 | 111 (24.18%) |
| N1 | 163 (35.52%) |
| N2 | 106 (23.09%) |
| N3 | 79 (17.21%) |
| Lauren classification | |
| Intestinal | 122 (26.58%) |
| Diffuse | 319 (69.50%) |
| Mixed | 18 (3.92%) |
| Methylated CpG site count | |
| 3 or less | 434 (94.55%) |
| 4 or more | 25 (5.45%) |
| Methylated status of CpG -515 | |
| Unmethylated | 431 (93.90%) |
| Methylated | 28 (6.10%) |
| Methylated status of CpG -435 | |
| Unmethylated | 432 (94.12%) |
| Methylated | 27 (5.88%) |
| Methylated status of CpG -430 | |
| Unmethylated | 420 (91.50%) |
| Methylated | 39 (8.50%) |